Online inquiry

IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14507MR)

This product GTTS-WQ14507MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14507MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10410MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ1920MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ2652MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ4700MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ4388MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ2403MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ15597MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ9360MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW